InfraScan lands regulatory approval for its next-generation Infrascanner Model 2000, designed with military specifications for non-invasively detecting bleeding in the brain.
Philadelphia-based medical device maker InfraScan announced FDA approval for its next-generation non-invasive brain bleed detector, the Infrascanner Model 2000.
Developed in partnership with the U.S. Navy and Marine Corps, the Infrascanner 2000 is a more rugged generation of the company's original Infrascanner, which won FDA approval in 2011.
The Infrascanner line uses near-infrared technology to non-invasively detect bleeding in the skull, helping to identify which patients may need a CT scan and quick intervention.
The company noted that, although it was developed to specifications necessary for military use, the new Infrascanner has applications in other fields, such as sports medicine.
"FDA approval in the U.S. allows InfraScan to offer an industry first, powerful tool for use by civilian and military medical professionals to quickly triage head trauma patients," InfraScan president & CEO Baruch Ben Dor said in prepared remarks. "Shortening the time to treatment through effective detection of intracranial bleeding can mean preserving brain function in a patient and even saving lives."
St. Jude Medical meets Wall Street's expectations for its 1st quarter of 2014 with moderate sales...
Here's a look at some of the top personnel stories for medical device companies this week.
Medical societies asked to name potentially needless treatments tend to leave out procedures that put...
Boston Scientific gets the FDA's OK for a new generation of defibrillators and heart failure devices...